CD19 and acute lymphoblastic leukemia: The treatment of B-ALL patients enrolled in the pediatric CTL019 trial (the University of Pennsylvania/Children’s Hospital of Philadelphia) with CD19-specific CAR-T cells led to the outgrowth of CD19-negative malignant clone, which retained the expression of an IL3 receptor α chain (CD123) (25).